In that module, the growth of in situ brain tumor was visible and quantitatively followed up with the expressions of luc and HSV1-tk, enlightening the access to examine the feasibility of candidates to serve as GBM drugs and/or radiosensitizers. The gene discussed is TKT; the disease is glioblastoma.